Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The McKesson Corporation (NYSE: MCK) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about McKesson’s healthcare services and pharmaceutical distribution activities, capital structure, governance, and financial reporting.
McKesson’s common stock and several series of notes, including 1.500% Notes due 2025, 1.625% Notes due 2026, and 3.125% Notes due 2029, are listed on the New York Stock Exchange, as shown in multiple Form 8-K filings. Filings such as Form 8-K report material events, including preliminary quarterly results, updated fiscal guidance, changes to reportable segments, and investor events like Investor Day. A Form 25 filing for 1.500% Notes due 2025 illustrates how specific debt securities can be removed from listing and registration on an exchange.
Investors can also review proxy materials, such as the definitive proxy statement (DEF 14A), which describes McKesson’s purpose, values, Board oversight, compensation matters, and shareholder voting results. These documents provide context on corporate governance, culture, and strategic priorities, including the company’s focus on North American pharmaceutical distribution, oncology and biopharma services platforms, and portfolio modernization.
On Stock Titan, SEC filings for MCK are updated from EDGAR and presented with AI-powered summaries designed to clarify key points in lengthy documents. Users can quickly identify the nature of each filing, from current reports on Form 8-K to proxy statements and other disclosures, and use AI-generated insights to understand segment changes, capital allocation decisions, and governance topics without reading every line of the underlying text.
This page is a useful starting point for reviewing McKesson’s regulatory history, tracking material events, and examining how the company communicates financial and strategic information through its SEC submissions.
McKesson Corporation has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer various securities from time to time after effectiveness. These may include common stock, preferred stock, depositary shares, debt securities, warrants, stock purchase contracts and stock purchase units, issued separately or in combination.
The company may sell these securities through underwriters, dealers, agents or directly to investors, using prospectus supplements to set specific terms for each offering. McKesson states that net proceeds will generally be used for corporate purposes such as repaying or redeeming debt or preferred stock, funding acquisitions and supporting working capital.
McKesson Corporation reports stronger results for the quarter ended December 31, 2025, with revenue rising to $106,158 million from $95,294 million and net income attributable to McKesson increasing to $1,186 million from $879 million. Diluted earnings per share grew to $9.59 from $6.95 as operating income rose to $1,619 million.
For the nine months, revenue reached $307,135 million and net income attributable to McKesson was $3,080 million, up from $2,035 million. The company completed major acquisitions of Vision Holdings and Core Ventures, adding significant goodwill and intangibles, funded partly by a $2.0 billion public debt offering.
McKesson ended the period with $2,959 million in cash and cash equivalents, total debt of $6,557 million, and opioid-related litigation liabilities of $5,708 million. Operating cash flow improved to $2,734 million for the nine months, while substantial share repurchases and dividends continued alongside ongoing restructuring and technology modernization initiatives.
McKesson Corporation filed a current report to furnish its preliminary financial results for the quarter ended December 31, 2025. The company states that these preliminary results are provided in an earnings release attached as Exhibit 99.1.
The report clarifies that the earnings information, including Exhibit 99.1, is being furnished to the SEC rather than filed, which affects how it may be used under certain securities law provisions. The filing is signed on behalf of McKesson by its Executive Vice President and Chief Financial Officer, Britt J. Vitalone.
McKesson Corp executive reports small stock sale under pre-set plan. On 01/05/2026, an officer of McKesson Corp, serving as EVP, Chief Strategy & BDO, sold 276 shares of common stock at a price of $816.18 per share. The filing states that this sale was made pursuant to a previously adopted Rule 10b5-1 trading plan dated August 18, 2025, which is designed to allow scheduled trades under predefined conditions. After this transaction, the officer directly held 2,268 shares of McKesson common stock.
A holder of MCK common stock has filed a notice of intent to sell 276 shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 01/05/2026. The filing reports an aggregate market value of 225265.68 for these shares.
The securities to be sold were acquired on 05/24/2022 through restricted stock vesting from the issuer, in the same amount of 276 common shares. The notice also states that there were 123426650 common shares outstanding at the time referenced, giving context for the planned sale size.
McKesson Corporation and the New York Stock Exchange are removing McKesson’s 1.500% Notes due 2025 from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The NYSE filed Form 25, certifying it has reasonable grounds to believe all requirements for delisting are met, and states that the exchange has complied with its rules to strike this debt security from listing. The filing also notes that McKesson has complied with the exchange’s rules and applicable SEC requirements governing the voluntary withdrawal of this class of notes from listing and registration.
McKesson (MCK) insider transaction: The company’s SVP, Controller & CAO reported a Form 4 sale of 329 shares of common stock at $861.63 per share on 11/07/2025 (transaction code S). The filing notes the trade was executed under a Rule 10b5‑1(c) plan adopted on 02/07/2025. Following the sale, the reporting person directly beneficially owned 328 shares.
McKesson Corporation reported stronger Q2 FY26 results. Revenue reached $103.15 billion, up from $93.65 billion a year ago, lifting gross profit to $3.54 billion. Operating income rose to $1.41 billion and net income attributable to McKesson increased to $1.11 billion, or $8.92 diluted EPS (vs. $1.87).
Results reflect lower operating expenses year over year and a $119 million discrete tax benefit, bringing the quarter’s reported tax rate to 16.6%. For the first half, revenue totaled $200.98 billion with net income attributable to McKesson of $1.89 billion and $15.16 diluted EPS. Cash from operations was $1.50 billion.
McKesson expanded its Oncology & Multispecialty segment with two deals: Core Ventures (70% for $2.5 billion) and PRISM Vision (80% for $871 million). It issued $2.0 billion of new notes (4.65% 2030, 4.95% 2032, 5.25% 2035) and ended the quarter with $4.00 billion in cash and $7.76 billion of total debt. The company classified its Norway businesses as held for sale, with net assets of $112 million. Shares outstanding were 123,426,650 as of October 31, 2025.
McKesson Corporation furnished preliminary results for the quarter ended September 30, 2025. The company provided these results in an earnings release attached as Exhibit 99.1, dated November 5, 2025. The information is being furnished to the SEC and is not deemed filed under the Exchange Act.
McKesson Corporation filed a current report to highlight its Investor Day and an accompanying news release that updates Fiscal 2026 guidance and long-term targets. The company is hosting its Investor Day, beginning at 9:30 a.m. Eastern time, with a live webcast and archived replay available through its investor relations website. The related news release is provided as Exhibit 99.1 and, along with this item, is being furnished to the SEC rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
McKesson Corporation filed a current report to highlight its Investor Day and an accompanying news release that updates Fiscal 2026 guidance and long-term targets. The company is hosting its Investor Day, beginning at 9:30 a.m. Eastern time, with a live webcast and archived replay available through its investor relations website. The related news release is provided as Exhibit 99.1 and, along with this item, is being furnished to the SEC rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.